North America Cell and Gene Therapy Manufacturing QC Market Size, Share & Trends Analysis Report By Therapy Type (Cell Therapy, Gene Therapy), By Scale (Pre-Commercial/R&D Manufacturing, Commercial Scale Manufacturing), By Mode (Contract Manufacturing, In-House Manufacturing), By Workflow (Cell Processing, Cell Banking, Fill & Finish Operations, Vector Production, Others), By Process (Upstream Processes, Downstream Processes), By End User (Pharmaceutical Companies, Contract Manufacturing Organizations), By Technology Type (Fluorescence-Activated Cell Sorting, Next-Generation Sequencing), By Country (U.S., Canada), Forecasts, 2026-2034

Last Updated: July 08, 2026 | Author: Debashree B | Format:

Market Segmentation

  1. North America Cell and Gene Therapy Manufacturing QC Market, By Therapy Type 2022-2034 (USD MILLION/ Units)
    1. Cell Therapy
      1. CAR-T
        1. Autologous CAR-T
        2. Allogeneic CAR-T
      2. CAR-NK
      3. B-Cell
      4. Others
    2. Gene Therapy
      1. Viral
        1. AAV
        2. Lentiviral vectors
        3. Other
      2. Non-Viral
  2. North America Cell and Gene Therapy Manufacturing QC Market, By Scale 2022-2034 (USD MILLION/ Units)
    1. Pre-commercial/ R&D Manufacturing
    2. Commercial Scale Manufacturing
  3. North America Cell and Gene Therapy Manufacturing QC Market, By Mode 2022-2034 (USD MILLION/ Units)
    1. Contract Manufacturing
    2. In-house Manufacturing
  4. North America Cell and Gene Therapy Manufacturing QC Market, By Workflow 2022-2034 (USD MILLION/ Units)
    1. Cell Processing
    2. Cell Banking
    3. Fill & Finish Operations
    4. Raw Material Testing
    5. Vector Production
    6. Other Workflows
  5. North America Cell and Gene Therapy Manufacturing QC Market, By Process 2022-2034 (USD MILLION/ Units)
    1. Upstream Processes
    2. Downstream Processes
  6. North America Cell and Gene Therapy Manufacturing QC Market, By End-User 2022-2034 (USD MILLION/ Units)
    1. Pharmaceutical Companies
      1. Small Size
      2. Medium Size
      3. Large Size
    2. Biopharmaceutical / Biotechnological Companies
      1. Small Size
      2. Medium Size
      3. Large Size
    3. Contract Manufacturing Organizations
      1. Small Size
      2. Medium Size
      3. Large Size
  7. North America Cell and Gene Therapy Manufacturing QC Market, By Technology Type 2022-2034 (USD MILLION/ Units)
    1. Fluorescence-Activated Cell Sorting (FACS)
    2. Enzyme-Linked Immunosorbent Assay (ELISA)
    3. Chromatography
    4. Next-Generation Sequencing (NGS)
    5. Polymerase Chain Reaction (PCR)
    6. Others
  8. Regional North America Cell and Gene Therapy Manufacturing QC Market
    1. North America
      1. North America North America Cell and Gene Therapy Manufacturing QC Market By Therapy Type 2022-2034 (USD MILLION/ Units)
        1. Cell Therapy
          1. CAR-T
            1. Autologous CAR-T
            2. Allogeneic CAR-T
          2. CAR-NK
          3. B-Cell
          4. Others
        2. Gene Therapy
          1. Viral
            1. AAV
            2. Lentiviral vectors
            3. Other
          2. Non-Viral
      2. North America North America Cell and Gene Therapy Manufacturing QC Market By Scale 2022-2034 (USD MILLION/ Units)
        1. Pre-commercial/ R&D Manufacturing
        2. Commercial Scale Manufacturing
      3. North America North America Cell and Gene Therapy Manufacturing QC Market By Mode 2022-2034 (USD MILLION/ Units)
        1. Contract Manufacturing
        2. In-house Manufacturing
      4. North America North America Cell and Gene Therapy Manufacturing QC Market By Workflow 2022-2034 (USD MILLION/ Units)
        1. Cell Processing
        2. Cell Banking
        3. Fill & Finish Operations
        4. Raw Material Testing
        5. Vector Production
        6. Other Workflows
      5. North America North America Cell and Gene Therapy Manufacturing QC Market By Process 2022-2034 (USD MILLION/ Units)
        1. Upstream Processes
        2. Downstream Processes
      6. North America North America Cell and Gene Therapy Manufacturing QC Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        2. Biopharmaceutical / Biotechnological Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        3. Contract Manufacturing Organizations
          1. Small Size
          2. Medium Size
          3. Large Size
      7. North America North America Cell and Gene Therapy Manufacturing QC Market By Technology Type 2022-2034 (USD MILLION/ Units)
        1. Fluorescence-Activated Cell Sorting (FACS)
        2. Enzyme-Linked Immunosorbent Assay (ELISA)
        3. Chromatography
        4. Next-Generation Sequencing (NGS)
        5. Polymerase Chain Reaction (PCR)
        6. Others
      8. U.S.
        1. Cell Therapy
          1. CAR-T
            1. Autologous CAR-T
            2. Allogeneic CAR-T
          2. CAR-NK
          3. B-Cell
          4. Others
        2. Gene Therapy
          1. Viral
            1. AAV
            2. Lentiviral vectors
            3. Other
          2. Non-Viral
        3. Pre-commercial/ R&D Manufacturing
        4. Commercial Scale Manufacturing
        5. Contract Manufacturing
        6. In-house Manufacturing
        7. Cell Processing
        8. Cell Banking
        9. Fill & Finish Operations
        10. Raw Material Testing
        11. Vector Production
        12. Other Workflows
        13. Upstream Processes
        14. Downstream Processes
        15. Pharmaceutical Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        16. Biopharmaceutical / Biotechnological Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        17. Contract Manufacturing Organizations
          1. Small Size
          2. Medium Size
          3. Large Size
        18. Fluorescence-Activated Cell Sorting (FACS)
        19. Enzyme-Linked Immunosorbent Assay (ELISA)
        20. Chromatography
        21. Next-Generation Sequencing (NGS)
        22. Polymerase Chain Reaction (PCR)
        23. Others
      9. Canada
        1. Cell Therapy
          1. CAR-T
            1. Autologous CAR-T
            2. Allogeneic CAR-T
          2. CAR-NK
          3. B-Cell
          4. Others
        2. Gene Therapy
          1. Viral
            1. AAV
            2. Lentiviral vectors
            3. Other
          2. Non-Viral
        3. Pre-commercial/ R&D Manufacturing
        4. Commercial Scale Manufacturing
        5. Contract Manufacturing
        6. In-house Manufacturing
        7. Cell Processing
        8. Cell Banking
        9. Fill & Finish Operations
        10. Raw Material Testing
        11. Vector Production
        12. Other Workflows
        13. Upstream Processes
        14. Downstream Processes
        15. Pharmaceutical Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        16. Biopharmaceutical / Biotechnological Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        17. Contract Manufacturing Organizations
          1. Small Size
          2. Medium Size
          3. Large Size
        18. Fluorescence-Activated Cell Sorting (FACS)
        19. Enzyme-Linked Immunosorbent Assay (ELISA)
        20. Chromatography
        21. Next-Generation Sequencing (NGS)
        22. Polymerase Chain Reaction (PCR)
        23. Others

We are featured on: